| .利妥昔单抗，来那度胺联合奥布替尼方案治疗
老年弥漫大B细胞淋巴瘤的临床观察[J].,2024,(24):4692-4694 |
| 利妥昔单抗，来那度胺联合奥布替尼方案治疗
老年弥漫大B细胞淋巴瘤的临床观察 |
| Clinical Observation of Rituximab, Lenalidomide Combined with Obutinibin the Treatment of Elderly Patients with Diffuse Large B-cell Lymphoma |
| 投稿时间：2024-08-20 修订日期：2024-09-05 |
| DOI：10.13241/j.cnki.pmb.2024.24.020 |
| 中文关键词: 弥漫大B细胞淋巴瘤 老年 利妥昔单抗 来那度胺 奥布替尼 |
| 英文关键词: Diffuse large B-cell lymphoma Old age Rituximab Lenalidomide Obutinib |
| 基金项目:新疆维吾尔自治区自然科学基金项目（2020D01C093） |
|
|
| 摘要点击次数: 12 |
| 全文下载次数: 7 |
| 中文摘要: |
| 摘要 目的： 探讨利妥昔单抗，来那度胺联合奥布替尼方案治疗老年弥漫大B细胞淋巴瘤的临床效果。方法：选取2020.5-2022.6收治的60例老年弥漫大B细胞淋巴瘤患者，分为对照组、观察组，各30例。对照组接受R-mini-CHOP方案化疗，观察组接受利妥昔单抗，来那度胺联合奥布替尼方案，比较两组相关指标。结果：观察组患者客观缓解率比对照组更高（P<0.05）；观察组治疗后CD3+、CD4+水平比对照组更高，CD8+水平比对照组更低（P<0.05）；观察组治疗期间毒副反应总发生率比对照组低（P<0.05）。两组中位PFS分别为14.9周（95%CI 12~17）和5.8周（95%CI 4~7）（P<0001），两组中位OS分别为20.1周（95%CI 16~22）和7.5周（95%CI 5~9）（P<0001）。结论：利妥昔单抗、来那度胺联合奥布替尼治疗可减轻老年弥漫大B细胞淋巴瘤患者免疫损伤，存在一定安全性，临床疗效显著。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of rituximab, lenalidomide combined with aubutinib in the treatment of elderly patients with diffuse large B-cell lymphoma. Methods: Sixty elderly patients with diffuse large B cell lymphoma admitted to 2020.5-2022.6 were divided into control group and observation group, with 30 patients each. The control group received chemotherapy with R-mini-CHOP regimen, and the observation group received rituximab, lenalidomide combined with obutinib regimen, to compare the relevant indicators between the two groups. Results: Patients in the observation group had higher rates of objective response than the control group(P<0.05); they had higher CD3+ and CD4+ levels, and lower CD8+ levels than the control group(P<0.05); the overall incidence of toxic effects during treatment was lower than in the control group (P<0.05). The median PFS was 14.9 (95% CI 12-17) and 5.8 (95% CI 4-7)(P<0001), and the median OS was 20.1 (95% CI 16-22) and 7.5 (95% CI 5-9) (P<0001). Conclusion: Treatment with rituximab and lenalidomide combined with obutinib can reduce the immune damage in elderly patients with diffuse large B cell lymphoma, with a certain safety profile and significant clinical efficacy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
